The thymus has long been viewed as an immune organ that fades into retirement after childhood. A new Nature study using AI and chest CT scans suggests that healthier-looking adult thymic tissue is associated with longer survival and lower risks of lung cancer and cardiovascular death—but the findings remain observational.

Heart disease rarely comes from a single broken switch. It usually develops through several interacting problems: blood pressure, cholesterol, smoking, blood-sugar control, body composition, inflammation, genetics, and time. A 2025 study asked whether combining two of those signals, inflammation and insulin resistance, might reveal cardiovascular risk more clearly than looking at either one alone [1].

Uric acid has a public-relations problem. Most people meet it through gout, kidney stones, or a laboratory result their doctor wants to lower. Yet uric acid is also one of the most abundant antioxidants circulating in human blood.

Coffee headlines tend to arrive with the confidence of a barista calling out an order: three cups are good, five cups are bad, and your genes decide the rest. The real evidence is more interesting and less tidy. Two large UK Biobank studies found that moderate coffee intake was associated with lower risks at several stages of chronic disease, while one of them also found higher risks among people drinking more than five cups a day.

The compound that makes tomatoes red has attracted attention far beyond the produce aisle. Lycopene is a carotenoid, a family of plant pigments that includes several substances with antioxidant activity. In laboratory research, lycopene has shown intriguing effects in models of brain injury, including models designed to imitate selected features of Parkinson's disease.

Aging biology has a wonderfully unfair habit: just when you think the plot is about genes, stem cells, or mitochondria, it points to something duller and more physical, like old proteins quietly getting chemically scuffed. The new Nature Communications paper from Trabosh and colleagues is about exactly that sort of damage, and its central claim is preliminary but genuinely interesting: an engineered enzyme called CMLase can remove a common aging-related protein modification called N-epsilon-carboxymethyl-lysine, or CML, from model proteins and from aged human tissue samples outside the body [1]. That is not the same as rejuvenating a person.

GLP-1 drugs have changed what is possible in obesity treatment. Semaglutide and related medicines can produce weight loss that once required bariatric surgery. But the number on the scale does not tell the whole story. When body weight falls, some of the loss comes from fat and some comes from lean tissue - a category that includes skeletal muscle, organs, connective tissue, water, and glycogen.

Search for sermorelin online and you will quickly find a familiar promise: better sleep, more muscle, less fat, faster recovery, sharper thinking, and perhaps even slower aging. The appeal is obvious. Sermorelin is often described as a gentler, more “natural” alternative to human growth hormone because it asks the body to release more of its own hormone rather than supplying growth hormone directly. That description contains real physiology. It also leaves out important facts. Sermorelin has legitimate medical history, but much of today’s anti-aging marketing reaches beyond the evidence. It is best understood as a short biological signal whose effects depend on the pituitary gland, the patient, and the reason it is prescribed.

Every few years, the wellness world finds a molecule and hands it a cape. Not a modest cardigan. A cape, flapping while someone on a podcast says “regeneration” like it is a sacrament. BPC-157 is one of those molecules. It is often called the “Wolverine peptide,” a warning sign because biology is not a Marvel franchise. The claim is seductive: faster tendon healing, calmer guts, less pain. Wonderful. Also: hold the parade. BPC-157 stands for Body Protection Compound-157. It is a short chain of amino acids, originally studied as a stable gastric pentadecapeptide - a 15-amino-acid fragment associated with stomach-related biology

A diabetes medicine has become one of the more interesting side stories in aging research. The drugs are called SGLT2 inhibitors, a mouthful of a name for medicines such as empagliflozin, dapagliflozin, and canagliflozin. They were first developed to help people with type 2 diabetes lower blood sugar. More recently, doctors have learned that some of these drugs can also protect the heart and kidneys. Now researchers are asking a newer question: could they also calm some of the cellular wear-and-tear linked with aging? A 2025 review in npj Aging argues that the idea is scientifically plausible, but still early [1].

Alzheimer's disease is usually discussed in terms of sticky amyloid plaques, tangled tau proteins, and the slow loss of memory. Those pieces still matter. But a new study adds another layer to the story: the way brain cells decorate proteins with sugar-based molecules. In a 2026 Nature Metabolism paper, researchers reported that brains affected by Alzheimer's disease showed unusually high levels of a process called glycosylation, and that pushing this process up or down changed memory-related behavior in mouse models [1].

Every cell in your body is a talker. Some cells communicate with electrical pulses, some with hormones, and many with tiny packages called extracellular vesicles, or EVs. Think of EVs as sealed envelopes released by cells into the fluid around them. Inside the envelope may be proteins, fats, pieces of genetic material, or chemical signals. Other cells can pick up these packages and change their behavior in response. That is useful when the message says, in effect, repair this tissue or calm this inflammation. It can be harmful when the message spreads stress, inflammation, or damaged cell parts.

Survodutide is not approved as a consumer treatment for fatty liver disease. That is the first bucket to keep the facts in. The second bucket is more interesting: a new phase 3 trial gives the drug a real reason to be watched closely. Phase 3 means the treatment has moved past small early studies and is being tested in a larger, more serious way before regulators decide what to do with it. The SYNCHRONIZE-MASLD study tested once-weekly survodutide, an injectable drug that turns on two body signaling systems: the glucagon receptor and the GLP-1 receptor. GLP-1 is the family of signals made famous by newer weight-loss and diabetes drugs. Glucagon is a different signal involved in how the body handles stored fuel. Put them together and you get a drug designed to push on weight, blood sugar, fat metabolism, and possibly the liver itself [1].

Artificial intelligence is not making aging disappear. Let's get that out of the way before the immortality kazoo parade starts honking its way down the hallway and somebody in a Patagonia vest tells you that death has been disrupted. It has not. Biology remains stubborn, damp, mutinous, and very fond of humiliating clean business plans. But AI is doing something real in longevity science: it is becoming a ferociously fast pattern-finder, the sort of tool that can rummage through genes, proteins, blood markers, medical records, imaging, drug structures, clinical trials, and wearable-device signals without needing coffee, tenure, or a sabbatical.

Most of us think about the body clock in ordinary terms: sleep, jet lag, late-night snacks, and the misery of daylight saving time. A 2026 Cell study takes that familiar idea into much deeper territory. Researchers reported that timed treatment with 3'-deoxyadenosine, also called 3dA or cordycepin, strengthened circadian rhythm amplitude in a small hypothalamic brain region called the paraventricular nucleus, or PVN. In aged male mice, that intervention improved several aging-related measures, reduced DNA-methylation age, restored hormonal synchrony, and extended lifespan

Rapamycin has become one of the most talked-about drugs in longevity circles. Depending on who is speaking, it is either the most promising geroprotector we have or a risky transplant drug being dragged too quickly into wellness culture. A 2026 randomized trial called RAPA-EX-01 gives the conversation something it badly needed: a real human result that was not especially flattering. In sedentary adults aged 65 to 85, weekly sirolimus, which is the medical name for rapamycin, did not improve the benefits of a 13-week exercise program. In some analyses, it may have slightly reduced gains in chair-stand performance, and the Sirolimus group had more adverse events

Let us begin with the fantasy, because the fantasy is doing most of the work here. You are tired. Your sleep is lousy. The gym used to reward you for showing up, and now it behaves like a bureaucrat who lost your paperwork. Then along comes sermorelin, a tidy little peptide with a lab-coat name and a seductive promise: nudge your pituitary, raise growth hormone, bring back some of the old biological swagger. Terrific. Also, hold on to your wallet and maybe your endocrine system.

If you hear the word “polyphenols” and immediately think “superfood marketing,” that reaction is fair. The term gets tossed around so often that it can sound like nutritional confetti. But polyphenols are real, and they matter. They are a large family of compounds made by plants, and they show up in foods many people already eat: berries, cocoa, tea, coffee, olives, extra-virgin olive oil, grapes, apples, onions, herbs, and many vegetables [1]. The honest question is not whether polyphenols exist or whether they can do interesting things in a lab. The real question is whether they help people live longer or age better.

Rapamycin, or sirolimus, has become one of the central drugs in the modern biology-of-aging conversation. The reason is simple: in animal studies it has repeatedly extended lifespan and improved several measures of late-life function, which is rare enough to command attention. That track record is why rapamycin moved from an interesting laboratory result to a serious human research question. The question now is not whether mTOR signaling matters in aging. It plainly does. The question is whether manipulating that pathway in people can improve healthspan in a way that is clinically meaningful and safe. Human evidence, as of May 4, 2026, is still early and mixed, but it is no longer speculative

Your immune system is basically a paranoid security guard, constantly patrolling your body and demanding to see everyone's credentials. Most of the time, this works beautifully—infected cells get escorted out, abnormal cells get eliminated, and you stay healthy.

by: Donna Wright

edited and approved by Stephen C. Rose, PhD

Get Packing, Vacations May Improve Longevity

Stop wasting your vacation days on oil changes, dentist appointments, and household admin. A vacation, in theory, should entail recovery from the stresses of everyday life. The evidence...

Donna Wright

Edited and approved by Stephen C. Rose, PhD

Brushing Your Teeth May Be More Important Than You Think

Most people first learn to brush their teeth to prevent cavities and bad breath. That is still true, but it is not the whole story. Oral health is tied to overall health in ways that...

Today, it seems, we’ve never been closer to a reality where our lifespan could become longer – much longer.

Of course, modern medicine is helping us live longer, healthier lives. But we could be on the brink of a transformational change.

We’re making progress toward slowing the aging process. We’re...